Current Affiliation Organization 【 display / non-display 】

Current Affiliation Organization 【 display / non-display 】

University 【 display / non-display 】

University 【 display / non-display 】

Graduate School 【 display / non-display 】

Graduate School 【 display / non-display 】

Study abroad experiences 【 display / non-display 】

Study abroad experiences 【 display / non-display 】

External Career 【 display / non-display 】

External Career 【 display / non-display 】

display all >>

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

display all >>

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Unequal distribution of plasma glucagon levels among clustering-based diabetes subtypes: a Japanese cohort.

  Tanabe H, Shimajiri Y, Shiroma K, Higa M, Masuzaki H, Shimabukuro M

  The Journal of clinical endocrinology and metabolism ( The Endocrine Society )    2025.12 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Abstract Context Hyperglucagonemia contributes to disturbances in glucose metabolism. Data-driven diabetes clustering reflects risk of diabetic complications better than classical classification, type 1 diabetes (T1D) vs. type 2 diabetes (T2D); however, the pathophysiological features have not been clarified. Objective To assess the distribution of plasma glucagon levels among clustering-based diabetes subtypes. Methods A total of 546 Japanese participants with T1D or T2D were categorized into five diabetes subtypes. Plasma glucagon levels were compared across subtypes and factors associated with hyperglucagonemia were evaluated using logistic regression analyses. Results Plasma glucagon levels differed significantly among diabetes subtypes. Among the five subtypes, plasma glucagon levels and the frequency of hyperglucagonemia were highest in the severe insulin-resistant diabetes (SIRD) subtype (45.6%). The SIRD subtype was an independent risk factor for hyperglucagonemia (adjusted odds ratio 2.17, 95%CI 1.03–4.54, P=0.041), even after adjusting for other risk factors, such as body mass index, HbA1c, and metabolic dysfunction-associated steatotic liver disease. Conclusion The distribution of plasma glucagon levels differed among the clustering-based diabetes subtypes. SIRD is a subtype of diabetes with a hyperglucagonemic phenotype. Elucidating the reason for hyperglucagonemia in SIRD may help to clarify the mechanisms underlying the unfavorable clinical phenotype.

  • Access this article

    DOI
  • Search related information
    PubMed

• SGLT-2 Inhibitors Are Potent to Suppress Aggressive Transformation From Indolent Type of Adult T-Cell Leukemia/Lymphoma: Unique Insight Into Therapeutics for Diabetes-Related Hematological Malignancy.

  Morichika K, Tamaki K, Fukushima T, Masuzaki H

  EJHaem   6 ( 5 ) e70109   2025.10 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  INTRODUCTION: We previously reported that sodium-glucose co-transporter 2 (SGLT-2) was ectopically overexpressed in adult T-cell leukemia (ATL) cells notably in aggressive type but in indolent type, and widely-used anti-diabetic SGLT-2 inhibitors (SGLT-2i) considerably attenuated proliferation of leukemic cells. METHODS: We performed retrospective analyses for 10 years to see whether SGLT-2i would prevent aggressive transformation in patients with indolent type ATL accompanied by diabetes. Nucleosome occupancy in the promotor region of the SGLT-2 gene was also assessed to explore the possible involvement of epigenetic modification in such an ectopic overexpression. RESULTS: In patients of indolent ATL with diabetes, the cumulative progression rate in the non-SGLT-2i-treated group was 71%, while no patients developed aggressive transformation in the SGLT-2i treated group. ATL cells showed an apparent trend to decrease nucleosome occupancy in the promotor region of the SGLT-2 gene. CONCLUSION: Our data suggest that SGLT-2i is advantageous for preventing aggravative transformation in indolent ATL. TRIAL REGISTRATION: Authors confirmed that clinical trial registration was not requested for the present study and this manuscript.

  • Access this article

    DOI
  • Search related information
    PubMed

• Extranodal natural killer/T-cell lymphoma with lung involvement in a young adult with suspected mosquito bite hypersensitivity: A case report.

  Higa M, Atsumi E, Hoshino H, Yamashiro M, Nakajima T, Tomita M, Masuzaki H, Wada N, Owan I

  Respiratory investigation ( Respiratory Investigation )  63 ( 5 ) 872 - 876   2025.07 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  A young adult with suspected pulmonary lymphoma was diagnosed with extranodal natural killer/T-cell lymphoma (ENKTL). The patient had a history of possible mosquito bite hypersensitivity (MBH), suggesting a potential association between MBH and ENKTL. Although ENKTL typically affects middle-aged adults, it has rarely been reported in children with MBH or chronic active Epstein-Barr virus (EBV) disease. This case highlights the challenges of obtaining pathological confirmation from small biopsy samples of pulmonary ENKTL. Detailed history taking and EBV DNA testing may aid in diagnosis, particularly in younger patients.

  • Access this article

    DOI
  • Search related information
    PubMed

• Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD).

  Nakamura Y, Horie I, Yano H, Nomoto H, Fukui T, Yuyama Y, Kawamura T, Ueda M, Yamamoto A, Hirota Y, Kusunoki Y, Nishida K, Sekiguchi D, Maeda Y, Minami M, Nagayama A, Iwata S, Minagawa H, Furukawa S, Miyake T, Ueno H, Chinen R, Nakayama Y, Masuzaki H, Miyachi Y, Okada Y, Okamoto M, Ono K, Tanaka KI, Kurozumi A, Sakai T, Yamasaki H, Yasui JI, Ito A, Kawakami A, Abiru N, IPRA-CKD Study Group

  Biomedicines ( Biomedicines )  13 ( 6 )   2025.05 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Background/Objectives: While sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated additional non-glycemic benefits for renal protection in individuals with type 2 diabetes, less evidence is available for those with type 1 diabetes (T1D). To determine whether the adjunctive use of the SGLT2 inhibitor ipragliflozin confers kidney protection in individuals with T1D, we retrospectively analyzed data from a real-world cohort examined at 25 centers in Japan. Methods: We enrolled 359 subjects aged 20-74 years with T1D (IPRA group: 159 ipragliflozin users; control [CTRL] group: 200 non-users). The primary outcome was changes in the estimated glomerular filtration rate (eGFR) from baseline to 24 months after the initiation of ipragliflozin. The secondary outcomes were all other changes, including the urinary albumin-creatinine ratio (UACR) and urinary protein-creatinine ratio (UPCR). Results: The IPRA group's eGFR decline slopes were 0.79 mL/min/1.73 m2/year milder than the CTRL group's after propensity score matching, but this difference was not significant. The subjects complicated by chronic kidney disease (CKD) defined as UACR ≥ 30 mg/g and/or UPCR ≥ 0.5 g/g and/or eGFR < 60 mL/min/1.73 m2 showed changes in UPCR (g/g) from baseline to 24 months that were significantly lower in the IPRA group (-0.27 ± 1.63) versus the CTRL group (0.18 ± 0.36) (p = 0.016). No significant increase in adverse events (including severe hypoglycemia and hospitalization due to ketosis/ketoacidosis or cardiovascular diseases) was observed in the IPRA group. Conclusions: Adjunctive treatment with ipragliflozin exerted potential renal benefits by decreasing proteinuria in T1D subjects with CKD. Further investigations are required to determine whether its additional benefits exceed the increased risk of ketoacidosis.

  • Access this article

    DOI
  • Search related information
    PubMed

• Two Cases of Plasmablastic Myeloma Mimicking Plasmablastic Lymphoma With In-Depth Review of Literature.

  Kitamura S, Morichika K, Nakachi S, Hanashiro T, Miyagi R, Nakajima T, Nishi Y, Tamaki K, Fukushima T, Masuzaki H

  Cancer reports (Hoboken, N.J.) ( Cancer Reports )  8 ( 2 ) e70094   2025.02 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article

    DOI
  • Search related information
    PubMed

display all >>

Books 【 display / non-display 】

Books 【 display / non-display 】

• Clinical Antiaging Medicine: Obesity, Metabolic Syndrome, and Antiaging Medicine

  Hiroaki Masuzaki ( Part: Multiple Authorship )

  springer  2025.02

• 米糠由来機能成分 γオリザノールを活用する脳機能改善・糖尿病予防のアプローチ

  益崎 裕章、小塚 智沙代、與那嶺 正人、島袋 充生 ( Part: Multiple Authorship )

  Society for Glycative Stress Research  2017

Other Papers 【 display / non-display 】

Other Papers 【 display / non-display 】

• Future prospects on 100 years healthy longevity brought by precision health and precision nutrition

  益崎裕章

  糖尿病と妊娠   25 ( 1 )   2025

   

  J-GLOBAL

• Brain science-based clinical approach for type 2 diabetes and obesity disease

  益崎裕章, 橋本龍馬, 伊敷洋平, 玉城敦子, 本間健一郎

  日本臨床   83   2025

   

  J-GLOBAL

• Current status of hematopoietic stem cell transplantation in Okinawa

  仲地佐和子, 北村紗希子, 森近一穂, 中島知, 宮城理子, 上間道仁, 横田雄太郎, 宮城敬, 狩俣かおり, 山入端敦, 大濱昌代, 友寄未希, 友寄毅昭, 森島聡子, 福島卓也, 益崎裕章

  日本造血・免疫細胞療法学会総会プログラム・抄録集   46th   2024

   

  J-GLOBAL

• Eleven of specific health disturbances essential for the diagnosis of obesity disease

  益崎裕章, 玉城敦子, 伊敷洋平, 本間健一郎

  日本臨床   82 ( 10 )   2024

   

  J-GLOBAL

• Obesity and obesity disease

  益崎裕章, 玉城敦子, 伊敷洋平, 中山良朗, 本間健一郎

  日本臨床   82   2024

   

  J-GLOBAL

display all >>

Presentations 【 display / non-display 】

Presentations 【 display / non-display 】

• 若年健康成人における腸内細菌叢（腸内フローラ）と食習慣に関する 観察研究

  上間 次己, 難波 豊隆, ジャスミン・フランシス・ミルマン, 赤嶺 ゆかり, 岡本 士毅, 益崎 裕章

  日本肥満学会  2019.11  -  2019.11 

• 沖縄 発：未来を託す子供たちに私たちが今、出来ること ～分子栄養学と脳科学からのアプローチ～

  益崎 裕章

  日本臨床内科医会  2019.10  -  2019.10 

• 合同シンポジウム１：全身加齢と局所変化

  益崎 裕章

  日本糖尿病合併症学会  2019.09  -  2019.09 

• 健康長寿社会に求められる食と行動の科学 ～沖縄の取り組みから～

  益崎 裕章, 小塚 智沙代, Jasmine F. Millman, 與那嶺 正人, 尾形 絵美, 山崎 聡, 島袋 充生, 岡本 士毅

  日本体質医学会  2019.08  -  2019.08 

Industrial Property 【 display / non-display 】

Industrial Property 【 display / non-display 】

• Metabolic Oncology

  Industrial Property No 2017-044254  (2017.04.03)

  Patent No 6015034  (2018.01.26)

Academic Awards 【 display / non-display 】

Academic Awards 【 display / non-display 】

• The Pfizer Scholars in Endocrinology Award in Recognition of Outstanding Achievement in the Advancement of Endocrinologic Science (USA)

  2013.03.15    

Grant-in-Aid for Scientific Research 【 display / non-display 】

Grant-in-Aid for Scientific Research 【 display / non-display 】

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2025.04  -  2028.03 

  Direct: 3,500,000 (YEN)  Overheads: 4,550,000 (YEN)  Total: 1,050,000 (YEN)

• Pathophysiologic molecular crosstalk in the brain between obese and alcohol-dependent states

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2024.04  -  2027.03 

  Direct: 3,600,000 (YEN)  Overheads: 4,680,000 (YEN)  Total: 1,080,000 (YEN)

• Pathophysiologic molecular crosstalk in the brain between obese and alcohol-dependent states

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2024.04  -  2027.03 

  Direct: 3,600,000 (YEN)  Overheads: 4,680,000 (YEN)  Total: 1,080,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2023.04  -  2026.03 

  Direct: 300,000 (YEN)  Overheads: 390,000 (YEN)  Total: 90,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2022.04  -  2025.03 

  Direct: 3,200,000 (YEN)  Overheads: 4,160,000 (YEN)  Total: 960,000 (YEN)

display all >>

Social Activity 【 display / non-display 】

Social Activity 【 display / non-display 】

• 2025.09

  　

  　

  

• 2024.03

  　

  　

  

• 2023.10

  　

  　

  

• 2023.04

  　

  　

  

• 2023.03

  　

  　

  

display all >>

Media Coverage 【 display / non-display 】

Media Coverage 【 display / non-display 】

• 30分以上の座位避けて：サルコペニア肥満の懸念  Newspaper, magazine

  沖縄タイムス  2023.2

  Author： Myself 

• 世界糖尿病デー：定期健診で早期発見重要  Newspaper, magazine

  沖縄タイムス  2022.11

  Author： Myself 

• 『長寿県沖縄』今は昔：沖縄復帰50周年  Internet

  時事通信デジタル  2022.5

  Author： Myself 

• 糖尿病薬で血液がん抑制  Newspaper, magazine

  琉球新報  2022.4

  Author： Myself 

• 今こそ栄養学のすすめ  Newspaper, magazine

  読売新聞  2021.1

  Author： Myself 

display all >>

Academic Activities 【 display / non-display 】

Academic Activities 【 display / non-display 】

• （ ホテル ザ・ナハテラス（沖縄県　那覇市） ）

  2024.8

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  金井好克先生 大阪大学 ヒューマン・メタバース疾患研究拠点 疾患代謝シグナル制御学　特任教授 特別講演：SGLT２阻害薬がもたらす２型糖尿病治療の新たな視点～創薬から振り返る～

• （ 沖縄ハーバービューホテル（沖縄県　那覇市） ）

  2024.8

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  山田裕揮先生 株式会社Medii 代表取締役 医師 基調講演：医師の調べ物改革：Chat GPTの上手な活用法

• （ ホテル ザ・ナハテラス（沖縄県　那覇市） ）

  2024.7

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  古川慎哉先生 愛媛大学 総合健康センター 教授 特別講演：睡眠障害と糖尿病：夜間頻尿を中心に

• 2024.6

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  寺内康夫先生　横浜市立大学大学院医学研究科 分子内分泌・糖尿病内科学 教授 特別講演：インクレチン製剤導入のポイント：DPP-4阻害薬と経口GLP-1受容体作動薬の使い分けを含めて

• （ 沖縄県立博物館・美術館（沖縄県　那覇市） ）

  2024.6

  　

  　

  種別： Academic society, research group, etc. 

  　View Summary

  桑原宏一郎先生　信州大学医学部循環器内科学教室 教授 特別講演：糖尿病合併高血圧患者の治療戦略：EAGLE-DH試験を含めて

display all >>